Posters
(results will display both Free Papers & Poster)
Long-term comparison of posterior capsule opacification with hydrophobic acrylic and hydrophilic acrylic intraocular lenses of 5 years follow-up: a randomized clinical trial
Poster Details
First Author: S.Vasavada INDIA
Co Author(s): A. Vasavada V. Vasavada M. Praveen S. Raj
Abstract Details
Purpose:
To compare posterior capsule opacification (PCO) 5 years postoperatively in contralateral eyes with a single-piece hydrophobic acrylic and 1 of 2 single-piece hydrophilic acrylic intraocular lenses (IOLs) with different configurations.
Setting:
Iladevi Cataract & IOL Research centre, Raghudeep Eye Hospital, Ahmedabad, India
Methods:
A prospective Randomized clinical trial of 68 patients enrolled. A hydrophobic AcrySof (hydrophobic group) or a hydrophilic C-flex (hydrophilic group C) or Akreos Adapt IOL (hydrophilic group A) was randomized for implantation in the fellow eye or vice versa of each patient. The Evaluation of Posterior Capsule Opacification (EPCO) area, EPCO score, was compared using digital photographs.
Results:
There was a significant decrease in EPCO PCO score and area with AcrySof compared against Akreos Adapt and Rayner IOL at 1, 3, 5 years postoperatively
Within the central 3 mm optic, there was a significant decrease in EPCO score and area with AcrySof compared against Akreos Adapt at 2, 3, 5 years follow up. At baseline and1 year there was no significant difference in PCO between the 2 IOLs. There was significant decrease in EPCO score, area with AcrySof at 3,5 years compared against Rayner, while at baseline,1, 2 years there was no significant difference between the 2 IOLs.
Conclusions:
The results in our study comparing single-piece acrylic IOLs of different material, optic design, and haptic configuration found that the 3 models had comparable PCO values at baseline. The single piece hydrophobic acrylic IOL with its aspheric optics was associated with lower PCO 5 years postoperatively than the 2 single-piece hydrophilic IOL models.
Financial Disclosure:
NONE